Antidepressant exposure in the womb, long treated with suspicion, now looks statistically innocent. A major register-based analysis comparing children of women who used antidepressants during pregnancy with those who stopped treatment before conception found no extra risk of autism spectrum disorder or attention-deficit/hyperactivity disorder once family background was fully accounted for.
The real signal, researchers argue, lies in shared vulnerability rather than the pills themselves. By using sibling comparisons, adjusting for parental psychiatric diagnoses, and controlling for socioeconomic status, the study shows that elevated rates of neurodevelopmental diagnoses track with genetic predisposition to depression and anxiety, not with selective serotonin reuptake inhibitor or other antidepressant exposure in utero. Raw associations faded after these confounders were modeled, a classic sign of indication bias rather than medication harm.
Clinical caution, the authors suggest, should shift from automatic fear of pharmacotherapy toward a more balanced risk–benefit calculus. Untreated maternal depression is linked to dysregulated hypothalamic–pituitary–adrenal axis activity and higher inflammatory markers, both of which may affect fetal brain development. For many patients, continuing evidence-based medication alongside psychological support may protect both parent and child more reliably than abrupt discontinuation driven by stigma.
